- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00281697
A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)
5. Juli 2013 aktualisiert von: Genentech, Inc.
A Phase III, Multicenter, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Treated Metastatic Breast Cancer
This phase III, multicenter, randomized, placebo-controlled, blinded trial is designed to evaluate the efficacy and safety of bevacizumab when combined with standard chemotherapy compared with chemotherapy alone in subjects with previously treated metastatic breast cancer.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
For all Outcome Measures except Overall Survival and One-year Survival, the Time Frame was from Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years 2 months).
For the Outcome Measures Overall Survival and One-year Survival, the Time Frame was from Baseline to the end of the study (up to 6 years, 7 months).
Studientyp
Interventionell
Einschreibung (Tatsächlich)
684
Phase
- Phase 3
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Signed informed consent form.
- ≥ 18 years of age.
- Histologically confirmed carcinoma of the breast with measurable or non-measurable metastatic disease that has progressed (patients with a history of brain metastasis are eligible for study participation [USA only], as long as their brain metastases have been treated and they have no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone).
- Progression of disease during or following administration of one (non-investigational) chemotherapy regimen administered in the first-line setting.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- For women of childbearing potential, use of an effective means of non-hormonal contraception.
- Life expectancy ≥ 3 months.
- Willingness and capacity to comply with study and follow-up procedures.
Exclusion Criteria:
- Prior hormonal therapy only as treatment for metastatic disease without chemotherapy. Patients must have received chemotherapy for their metastatic disease in the first-line setting. Hormone therapy alone is not allowed.
- For subjects who have received prior anthracycline-based therapy, documentation of left ventricular ejection fraction < 50% by either multiple gated acquisition (MUGA) or echocardiogram (ECHO).
- Treatment with more than one prior cytotoxic regimen for metastatic breast cancer (MBC).
- HER2-positive status (patients who have unknown HER2 status, and for whom determination of HER2 status is not possible, are eligible for this study).
- Unknown estrogen receptor (ER) and progesterone receptor (PR) status.
- Radiation therapy other than for palliation or brain metastasis, biologic therapy, or chemotherapy for MBC within 21 days prior to Day 0 (Day 1 of Cycle 1 of treatment).
- Prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) pathway-targeted therapy.
- Untreated brain metastasis.
- Inadequately controlled hypertension.
- Unstable angina.
- New York Heart Association Grade II or greater congestive heart failure (CHF).
- History of myocardial infarction within 6 months prior to Day 0 (the day of the first bevacizumab/placebo infusion).
- History of stroke or transient ischemic attack within 6 months prior to Day 0.
- Clinically significant peripheral vascular disease.
- Evidence of bleeding diathesis or coagulopathy.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0; anticipation of need for major elective surgical procedure during the study.
- Minor surgical procedures, fine-needle aspirations, or core biopsies within 7 days prior to Day 0.
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0.
- Serious, non-healing wound, ulcer, or bone fracture.
- History of anaphylactic reaction to monoclonal antibody therapy not controlled with treatment premedication.
- History of other malignancies within 5 years of Day 0, except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
- inadequate organ function.
- Pregnancy (positive serum pregnancy test) or lactation.
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the subject at high risk from treatment complications.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Standard chemotherapy + bevacizumab
Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.
|
The dose of bevacizumab was based on a patient's weight at baseline and remained the same throughout the study.
Andere Namen:
Patients received one of the following four standard chemotherapies for metastatic breast cancer.
|
Placebo-Komparator: Standard chemotherapy + placebo
Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.
|
Patients received one of the following four standard chemotherapies for metastatic breast cancer.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Progression-free Survival
Zeitfenster: Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)
|
PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first.
For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions.
For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions.
Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically.
All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.
|
Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Progression-free Survival Within Individual Standard Chemotherapy Cohorts (Taxanes, Gemcitabine, Capecitabine, and Vinorelbine)
Zeitfenster: Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)
|
Progression-free survival was defined as the time from randomization to first documented disease progression as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first.
Results are reported for each of the 4 standard chemotherapy cohorts used in the study.
|
Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)
|
Overall Survival
Zeitfenster: Baseline to the end of the study (up to 6 years, 7 months)
|
Overall survival was defined as the time from randomization to death from any cause.
|
Baseline to the end of the study (up to 6 years, 7 months)
|
One-year Survival
Zeitfenster: Baseline to the end of the study (up to 6 years, 7 months)
|
Percentage of patients who survived 1 year in the study.
|
Baseline to the end of the study (up to 6 years, 7 months)
|
Objective Response
Zeitfenster: Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)
|
A patient had an objective response if they had a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart as determined by the investigator using RECIST.
For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.
For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.
|
Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)
|
Duration of Objective Response
Zeitfenster: Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)
|
Duration of objective response was defined as the time from the initial response to documented disease progression or death from any cause, whichever occurred first.
Duration of objective response was only analyzed in patients who achieved an objective response.
|
Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Studienleiter: Leo Faoro, MD, Genentech, Inc.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Februar 2006
Primärer Abschluss (Tatsächlich)
1. März 2009
Studienabschluss (Tatsächlich)
1. September 2012
Studienanmeldedaten
Zuerst eingereicht
23. Januar 2006
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
23. Januar 2006
Zuerst gepostet (Schätzen)
25. Januar 2006
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
26. Juli 2013
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
5. Juli 2013
Zuletzt verifiziert
1. Juli 2013
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- AVF3693g
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Metastasierter Brustkrebs
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
Klinische Studien zur Placebo
-
SamA Pharmaceutical Co., LtdUnbekanntAkute Bronchitis | Akute Infektion der oberen AtemwegeKorea, Republik von
-
National Institute on Drug Abuse (NIDA)AbgeschlossenCannabiskonsumVereinigte Staaten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAbgeschlossenMännliche Probanden mit Typ-II-Diabetes (T2DM)Deutschland
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Abgeschlossen
-
Soroka University Medical CenterAbgeschlossen
-
Regado Biosciences, Inc.AbgeschlossenGesunder FreiwilligerVereinigte Staaten
-
Texas A&M UniversityNutraboltAbgeschlossenGlucose and Insulin Response
-
Longeveron Inc.BeendetHypoplastisches LinksherzsyndromVereinigte Staaten
-
Heptares Therapeutics LimitedAbgeschlossenPharmakokinetik | SicherheitsproblemeVereinigtes Königreich